175 related articles for article (PubMed ID: 37173640)
1. Tumor-stroma ratio predicts prognosis and PD-L1 expression in hepatocellular carcinoma.
Wang D; Luo J; Tao Y
BMC Cancer; 2023 May; 23(1):434. PubMed ID: 37173640
[TBL] [Abstract][Full Text] [Related]
2. Tumor-stroma ratio is a prognostic factor for survival in hepatocellular carcinoma patients after liver resection or transplantation.
Lv Z; Cai X; Weng X; Xiao H; Du C; Cheng J; Zhou L; Xie H; Sun K; Wu J; Zheng S
Surgery; 2015 Jul; 158(1):142-50. PubMed ID: 25890776
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy.
Umemoto Y; Okano S; Matsumoto Y; Nakagawara H; Matono R; Yoshiya S; Yamashita Y; Yoshizumi T; Ikegami T; Soejima Y; Harada M; Aishima S; Oda Y; Shirabe K; Maehara Y
J Gastroenterol; 2015 Jan; 50(1):65-75. PubMed ID: 24509608
[TBL] [Abstract][Full Text] [Related]
4. Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation.
Itoh S; Yoshizumi T; Yugawa K; Imai D; Yoshiya S; Takeishi K; Toshima T; Harada N; Ikegami T; Soejima Y; Kohashi K; Oda Y; Mori M
Hepatology; 2020 Dec; 72(6):1987-1999. PubMed ID: 32112577
[TBL] [Abstract][Full Text] [Related]
5. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma.
Liu CQ; Xu J; Zhou ZG; Jin LL; Yu XJ; Xiao G; Lin J; Zhuang SM; Zhang YJ; Zheng L
Br J Cancer; 2018 Jul; 119(1):80-88. PubMed ID: 29921949
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Stroma Ratio and Programmed Cell Death Ligand 1 Expression in Preoperative Biopsy and Matched Laryngeal Carcinoma Surgical Specimen.
Alessandrini L; Franz L; Sbaraglia M; Saccardo T; Cappello F; Drigo A; Frigo AC; Marioni G
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887397
[TBL] [Abstract][Full Text] [Related]
7. [A new prognostic score system of hepatocellular carcinoma following hepatectomy].
Wang YK; Bi XY; Li ZY; Zhao H; Zhao JJ; Zhou JG; Huang Z; Zhang YF; Li MX; Chen X; Wu XL; Mao R; Hu XH; Hu HJ; Liu JM; Cai JQ
Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):903-909. PubMed ID: 29262506
[No Abstract] [Full Text] [Related]
8. Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis.
Li JH; Ma WJ; Wang GG; Jiang X; Chen X; Wu L; Liu ZS; Zeng XT; Zhou FL; Yuan YF
Front Immunol; 2018; 9():2077. PubMed ID: 30254644
[No Abstract] [Full Text] [Related]
9. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.
Tan S; Guo X; Bei C; Zhang H; Li D; Zhu X; Tan H
BMC Cancer; 2022 Aug; 22(1):905. PubMed ID: 35986302
[TBL] [Abstract][Full Text] [Related]
11. Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels.
Sideras K; de Man RA; Harrington SM; Polak WG; Zhou G; Schutz HM; Pedroza-Gonzalez A; Biermann K; Mancham S; Hansen BE; Bart Takkenberg R; van Vuuren AJ; Pan Q; Ijzermans JNM; Sleijfer S; Sprengers D; Dong H; Kwekkeboom J; Bruno MJ
Sci Rep; 2019 Jul; 9(1):10677. PubMed ID: 31337865
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
[TBL] [Abstract][Full Text] [Related]
13. PD-L1
Zhou L; Wang J; Lyu SC; Pan LC; Shi XJ; Du GS; He Q
Technol Cancer Res Treat; 2021; 20():15330338211045820. PubMed ID: 34605709
[No Abstract] [Full Text] [Related]
14. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
15. Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients.
El-Gebaly F; Abou-Saif S; Elkadeem M; Helmy A; Abd-Elsalam S; Yousef M; Elkhouly RA; Amer IF; El-Demerdash T
Curr Cancer Drug Targets; 2019; 19(11):896-905. PubMed ID: 31538897
[TBL] [Abstract][Full Text] [Related]
16. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma.
Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Morinaga A; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
Hepatol Commun; 2021 Feb; 5(2):334-348. PubMed ID: 33553979
[TBL] [Abstract][Full Text] [Related]
17. High level of intercellular adhesion molecule-1 affects prognosis of patients with hepatocellular carcinoma.
Zhu PP; Yuan SG; Liao Y; Qin LL; Liao WJ
World J Gastroenterol; 2015 Jun; 21(23):7254-63. PubMed ID: 26109813
[TBL] [Abstract][Full Text] [Related]
18. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma.
Huang CY; Wang Y; Luo GY; Han F; Li YQ; Zhou ZG; Xu GL
J Immunother; 2017; 40(9):323-333. PubMed ID: 29028787
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of inflammatory biomarkers in hepatocellular carcinoma following hepatic resection.
Itoh S; Yugawa K; Shimokawa M; Yoshiya S; Mano Y; Takeishi K; Toshima T; Maehara Y; Mori M; Yoshizumi T
BJS Open; 2019 Aug; 3(4):500-508. PubMed ID: 31388642
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy.
Chen W; Hu S; Liu Z; Sun Y; Wu J; Shen S; Peng Z
Hepatol Int; 2023 Apr; 17(2):406-416. PubMed ID: 36645648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
